Posted by Michael Wonder on 23 Nov 2022
Pacylex granted FDA fast track designation for PCLX-001 for the treatment of relapsed or refractory acute myeloid leukaemia
22 November 2022 - Pacylex today announced that the US FDA has granted PCLX-001 fast track designation for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia.
PCLX-001 is a first in class N-myristoyltransferase inhibitor which inhibits signalling necessary for cancer cell proliferation and survival in leukaemia and lymphoma.
